Taken together, these intriguing data implicate NOX4-mediated signalling as a critical regulator of angiogenic capacity in both experimental and clinical diabetes and highlight this novel axis as a potential target towards improving vasoreparative function and resilience of circulating ECFCs within diabetic patients who are highly susceptible to both onset and progression of ischaemic CVD. This evidence concerns the gene NOX4 and diabetes mellitus.